Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
ABSTRACT Objective: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) enzyme levels were investigated in patients with epilepsy, epileptic seizure, remission period, and healthy individuals. Methods: Three main groups were evaluated, including epileptic seizure, patients with epilepsy in the non-seizure period, and healthy volunteers. The patients having a seizure in the Emergency department or brought by a postictal confusion were included in the epileptic attack group. The patients having a seizure attack or presenting to the Neurology outpatient department for follow up were included in the non-seizure (remission period) group. Results: The UCH-L1 enzyme levels of 160 patients with epilepsy (80 patients with epileptic attack and 80 patients with epilepsy in the non-seizure period) and 100 healthy volunteers were compared. Whereas the UCH-L1 enzyme levels were 8.30 (IQR=6.57‒11.40) ng/mL in all patients with epilepsy, they were detected as 3.90 (IQR=3.31‒7.22) ng/mL in healthy volunteers, and significantly increased in numbers for those with epilepsy (p<0.001). However, whereas the UCH-L1 levels were 8.50 (IQR=6.93‒11.16) ng/mL in the patients with epileptic seizures, they were 8.10 (IQR=6.22‒11.93) ng/mL in the non-seizure period, and no significant difference was detected (p=0.6123). When the UCH-L1 cut-off value was taken as 4.34 mg/mL in Receiver Operating Characteristic (ROC) Curve analysis, the sensitivity and specificity detected were 93.75 and 66.00%, respectively (AUG=0.801; p<0.0001; 95%CI 0.747‒0.848) for patients with epilepsy. Conclusion: Even though UCH-L1 levels significantly increased more in patients with epilepsy than in healthy individuals, there was no difference between epileptic seizure and non-seizure periods.
Main Authors: | , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Academia Brasileira de Neurologia - ABNEURO
2020
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000700424 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0004-282X2020000700424 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0004-282X20200007004242020-07-29Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsyYASAK,Ibrahim HalilYILMAZ,MustafaGÖNEN,MuratATESCELIK,MetinGURGER,MehtapILHAN,NevinGOKTEKIN,Mehmet Cagri Epilepsy Ubiquitin Seizures ABSTRACT Objective: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) enzyme levels were investigated in patients with epilepsy, epileptic seizure, remission period, and healthy individuals. Methods: Three main groups were evaluated, including epileptic seizure, patients with epilepsy in the non-seizure period, and healthy volunteers. The patients having a seizure in the Emergency department or brought by a postictal confusion were included in the epileptic attack group. The patients having a seizure attack or presenting to the Neurology outpatient department for follow up were included in the non-seizure (remission period) group. Results: The UCH-L1 enzyme levels of 160 patients with epilepsy (80 patients with epileptic attack and 80 patients with epilepsy in the non-seizure period) and 100 healthy volunteers were compared. Whereas the UCH-L1 enzyme levels were 8.30 (IQR=6.57‒11.40) ng/mL in all patients with epilepsy, they were detected as 3.90 (IQR=3.31‒7.22) ng/mL in healthy volunteers, and significantly increased in numbers for those with epilepsy (p<0.001). However, whereas the UCH-L1 levels were 8.50 (IQR=6.93‒11.16) ng/mL in the patients with epileptic seizures, they were 8.10 (IQR=6.22‒11.93) ng/mL in the non-seizure period, and no significant difference was detected (p=0.6123). When the UCH-L1 cut-off value was taken as 4.34 mg/mL in Receiver Operating Characteristic (ROC) Curve analysis, the sensitivity and specificity detected were 93.75 and 66.00%, respectively (AUG=0.801; p<0.0001; 95%CI 0.747‒0.848) for patients with epilepsy. Conclusion: Even though UCH-L1 levels significantly increased more in patients with epilepsy than in healthy individuals, there was no difference between epileptic seizure and non-seizure periods.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.78 n.7 20202020-07-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000700424en10.1590/0004-282x20200040 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
YASAK,Ibrahim Halil YILMAZ,Mustafa GÖNEN,Murat ATESCELIK,Metin GURGER,Mehtap ILHAN,Nevin GOKTEKIN,Mehmet Cagri |
spellingShingle |
YASAK,Ibrahim Halil YILMAZ,Mustafa GÖNEN,Murat ATESCELIK,Metin GURGER,Mehtap ILHAN,Nevin GOKTEKIN,Mehmet Cagri Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy |
author_facet |
YASAK,Ibrahim Halil YILMAZ,Mustafa GÖNEN,Murat ATESCELIK,Metin GURGER,Mehtap ILHAN,Nevin GOKTEKIN,Mehmet Cagri |
author_sort |
YASAK,Ibrahim Halil |
title |
Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy |
title_short |
Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy |
title_full |
Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy |
title_fullStr |
Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy |
title_full_unstemmed |
Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy |
title_sort |
evaluation of ubiquitin c-terminal hydrolase-l1 enzyme levels in patients with epilepsy |
description |
ABSTRACT Objective: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) enzyme levels were investigated in patients with epilepsy, epileptic seizure, remission period, and healthy individuals. Methods: Three main groups were evaluated, including epileptic seizure, patients with epilepsy in the non-seizure period, and healthy volunteers. The patients having a seizure in the Emergency department or brought by a postictal confusion were included in the epileptic attack group. The patients having a seizure attack or presenting to the Neurology outpatient department for follow up were included in the non-seizure (remission period) group. Results: The UCH-L1 enzyme levels of 160 patients with epilepsy (80 patients with epileptic attack and 80 patients with epilepsy in the non-seizure period) and 100 healthy volunteers were compared. Whereas the UCH-L1 enzyme levels were 8.30 (IQR=6.57‒11.40) ng/mL in all patients with epilepsy, they were detected as 3.90 (IQR=3.31‒7.22) ng/mL in healthy volunteers, and significantly increased in numbers for those with epilepsy (p<0.001). However, whereas the UCH-L1 levels were 8.50 (IQR=6.93‒11.16) ng/mL in the patients with epileptic seizures, they were 8.10 (IQR=6.22‒11.93) ng/mL in the non-seizure period, and no significant difference was detected (p=0.6123). When the UCH-L1 cut-off value was taken as 4.34 mg/mL in Receiver Operating Characteristic (ROC) Curve analysis, the sensitivity and specificity detected were 93.75 and 66.00%, respectively (AUG=0.801; p<0.0001; 95%CI 0.747‒0.848) for patients with epilepsy. Conclusion: Even though UCH-L1 levels significantly increased more in patients with epilepsy than in healthy individuals, there was no difference between epileptic seizure and non-seizure periods. |
publisher |
Academia Brasileira de Neurologia - ABNEURO |
publishDate |
2020 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000700424 |
work_keys_str_mv |
AT yasakibrahimhalil evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy AT yilmazmustafa evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy AT gonenmurat evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy AT atescelikmetin evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy AT gurgermehtap evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy AT ilhannevin evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy AT goktekinmehmetcagri evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy |
_version_ |
1756374799405285376 |